Do In-vitro dissolution rates differ between beclomethasone dipropionate particles generated from solution-based pMDIs formulated with HFA134a, HFA152a and HFO1234ze(E) propellants?

Hui Xin Ong, Nirmal Marasini, Lingzhe Rao, Daniel J. Duke, Damon Honnery, Stephen Stein, Benjamin Myatt, Phil Cocks, Paul Young

Research output: Chapter in Book/Report/Conference proceedingConference PaperOther


The switch from Hydrofluoroalkane 134a (HFA134a), with relatively high global warming potential (GWP), traditionally used in pressurised metered-dose inhalers (pMDI) to low GWP propellants HFO1234ze(E) and HFA152a is currently underway, posing numerous scientific questions and challenges to formulation development. This study aims to investigate the morphological properties of maturated beclomethasone dipropionate (BDP) particles generated from solution-based pMDIs formulated with three different propellants and the impact of these characteristics on in-vitro drug dissolution. To achieve this, a modified Andersen Cascade Impactor (ACI) that incorporates SnapwellTM inserts on a 3D-printed ACI plate was used to deposit and study the aerosol particles of specific aerodynamic size ranges produced from the three different pMDI formulations. The Snapwell insert was then used as a micro-dissolution apparatus. The dissolution rate of the drug particles over four hours showed the following rank order: HFA134a > HFO1234ze(E) > HFA152a. This could be attributed to the morphologies of the drug particles found on stage 5 of the ACI where HFA134a produced maturated particles with the smallest geometric size of both the corrugated/rough (1.45 µm) and smooth/spherical particles (0.78 µm) with a higher percentage (53%) of rough/irregular particles in comparison with HFO1234ze(E) and HFA152a formulations. From these initial findings, a thorough investigation into the morphology and dissolution performance in combination with detailed physicochemical profiles and aerosol performance of the particles is required to understand the effect of the new propellants when formulating next the generation low GWP pMDIs.
Original languageEnglish
Title of host publicationProceedings of Drug Delivery to the Lungs 2023
Place of PublicationEdinburgh, UK
PublisherThe Aerosol Society
Publication statusPublished - 2023
EventDrug Delivery to the Lungs 2023 - Sydney, Australia
Duration: 6 Dec 20238 Dec 2023 (Proceedings and Website)


ConferenceDrug Delivery to the Lungs 2023
Abbreviated titleDDL 2023
Internet address

Cite this